Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common allergy drug may heal brain damage in preterm infants

NCT ID NCT07688746

Not yet recruiting Disease control Sponsor: Bridget LaMonica Ostrem, M.D., Ph.D. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether clemastine, an allergy medicine, is safe for premature babies with white matter injury—a common brain injury in infants born early. Researchers will give the drug by mouth to 24 babies born at or before 32 weeks and now between 35 and 41 weeks old. The goal is to check for side effects and learn how the drug moves through their bodies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
clemastine (an antihistamine drug)
What this could lead to
If safe, this could point toward a treatment to repair brain damage in premature infants.
What could go wrong
This is an early, small safety study in 24 babies, so it may not show benefit or could reveal unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN INJURY, FETUS AND NEONATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain injury perinatal asphyxia periventricular leukomalacia Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN INJURY, FETUS AND NEONATE NEONATAL BRAIN INJURY PERIVENTRICULAR LEUKOMALACIA PERIVENTRICULAR WHITE MATTER ABNORMALITIES WHITE MATTER INJURY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • University of California, San Francisco

    San Francisco, California, 94158, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.